Neuland Laboratories

Neuland Laboratories EPS

The Earnings per Share (EPS) of Neuland Laboratories (NEULANDLAB.NS) as of Oct 29, 2026 is 283.71 INR. In the previous year, Earnings per Share (EPS) was 202.74 INR — a change of 39.94% (higher).

EPS

283.71INR

YoY

39.94%

Last updated:

Earnings per Share (EPS) of Neuland Laboratories is 2026 283.71 INR. Earnings per Share (EPS) of Neuland Laboratories was 2025 202.74 INR. It decreases by 39.94% higher compared to the previous year.

The Neuland Laboratories EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
49.74 INR
Jan 1, 2023
127.45 INR
Jan 1, 2024
233.89 INR
Jan 1, 2025
202.74 INR
Jan 1, 2026
283.71 INR
Jan 1, 2027 (e)
359.83 INR
Jan 1, 2028 (e)
484.95 INR
Jan 1, 2029 (e)
626.05 INR
The Neuland Laboratories EPS history
YEAREPSYoY
est626.05INR+29.10%
est484.95INR+34.77%
est359.83INR+26.83%
283.71INR+39.94%
202.74INR-13.32%
233.89INR+83.51%
127.45INR+156.22%
49.74INR-20.83%
62.83INR+397.24%
12.64INR-1.40%
12.82INR+36.18%
9.41INR-82.17%
52.77INR+71.51%
30.77INR+147.53%
12.43INR-40.51%
20.89INR+93.35%
10.81INR+441.39%
2.00INR-51.58%
4.12INR-176.60%
-5.38INR-129.49%
18.25INR+5.03%
17.37INR+25.60%
13.83INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Earnings per Share (EPS) of Neuland Laboratories is 283.71 INR in 2026.

Earnings per Share (EPS) of Neuland Laboratories changed from 202.74 INR to 283.71 INR, representing a 39.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neuland Laboratories

All Key Metrics — Neuland Laboratories